Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.54 |
| ▸ | HCK | P08631 | 6/20 | 0.54 |
| ▸ | TNF | P01375 | 3/20 | 0.53 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | MUSK | O15146 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4464165 | 0.92 | MAPK14 (0.49) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL13708149 | 0.88 | MAPK14 (0.55) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL4471507 | 0.87 | MAPK14 (0.53) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL13708144 | 0.87 | MAPK14 (0.57) | MAPK14MAPK12MAPK13MAPK11SRC | |
| Hydrochloric Acid SCHEMBL4465045 | 0.86 | MAPK14 (0.56) | MAPK14MAPK12MAPK13MAPK11SRC | |
| SCHEMBL4466421 | 0.86 | MAPK14 (0.52) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL3419400 | 0.83 | MAPK14 (0.56) | MAPK14MAPK12MAPK13MAPK11BRAF | |
| SCHEMBL4480498 | 0.81 | MAPK14 (0.47) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL3171155 | 0.80 | MAPK14 (0.54) | MAPK14MAPK12MAPK13MAPK11DDR2 | |
| SCHEMBL3423893 | 0.80 | MAPK14 (0.62) | MAPK14MAPK12MAPK13MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582638-B2 | Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | ELI LILLY AND COMPANY | 2008-11-06 | — | — | US | disclosed |
| WO-2007053346-A1 | PYRAZOLE-ISOQUINOLINE UREA DERIVATIVES AS P38 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275056-A1 | With improved potency and greater bioavailability; 1-{1-[1-(1-Methyl-cyclopropanecarbonyl)-piperidin-4-yloxy]-isoquinolin-4-yl}-3-[5-(1-methyl-cyclopropyl)-2-p-tolyl-2H-pyrazol-3-yl]-urea; antimetastasis and antineoplastic agents, rheumatoid arthritis | CNKSR1, CHUK, SLC14A1 | MAPK14 72/4885MAPK12 186/4885MAPK13 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.